Kenneth L Londoner

CEO of BioSig Technologies

BioSig Technologies, Inc.

Manhattan, USA United States

About Me

Kenneth L Londoner serves as the CEO of medical device company BioSig Technologies. This company was founded by Londoner in 2009. It has developed the PURE EP system. This is a system designed to improve Atrial Fibrillation and Ventricular Tachycardia. This is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system. Also, Londoner is the Managing Partner of Endicott Management Partners, LLC. This firm assists emerging growth companies in their corporate development and investing needs. Kenneth L Londoner previously was the executive vice president of NewCardio, Inc., a Silicon Valley based cardiac software company. He served at this position from April 2007 to October 2009. Moreover, from May 2012 to March 2014, Londoner worked at Alliqua BioMedical.

Interested in solutions for:

For my portfolio

I am looking for healthcare innovations:

You have not backed any projects. Lets change that!
Discover Projects

No project created yet. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.